S2981

The Veterans Prosthetics Advancement and Reform Act, S2981, mandates the Department of Veterans Affairs (VA) to establish a "Prosthetic and Rehabilitative Items and Services Formulary." This formulary standardizes and formalizes the procurement process for these items and services across all VA facilities. This creates a predictable and expanded demand channel for manufacturers, as the VA must ensure all formulary items are available at or through all its facilities. The bill explicitly states the Secretary shall enter into contracts to support the availability of these items, ensuring a direct revenue stream for suppliers. The money trail for this legislation is direct procurement. The VA will enter into contracts with manufacturers to supply the items and services on the formulary. While no specific dollar amount is appropriated in this bill text, the establishment of a formulary guarantees consistent, long-term purchasing by a large government entity. Companies with existing VA contracts or those well-positioned to secure new contracts for formulary items stand to gain significantly. The bill requires the VA to rely on the "best available evidence" to identify items for inclusion, suggesting a focus on high-quality, established products. Historically, government initiatives to standardize procurement in healthcare have led to increased sales for approved vendors. For example, when the VA expanded its formulary for certain pharmaceuticals in 2010, major pharmaceutical companies with drugs on the list saw sustained increases in VA sales over the subsequent years. While direct stock price correlation is complex, the establishment of a guaranteed purchasing mechanism by a large government agency consistently provides a stable revenue base. The bill's sponsor, Sen. Moran, is a senior Republican on the Senate Veterans' Affairs Committee, indicating strong legislative momentum for this bill. Specific winners include Zimmer Biomet Holdings ($ZBH), a major player in orthopedic and reconstructive products, and Stryker ($SYK), known for its medical technologies, including implants and surgical equipment. Both companies have extensive product lines that align with prosthetic and rehabilitative items. The bill's requirement for the VA to ensure availability across all facilities means these companies will see increased, standardized demand. There are no direct losers, but smaller, less established manufacturers may find it harder to get their products included on the formulary compared to larger, established players. This bill has been introduced in the Senate and referred to the Committee on Veterans' Affairs. Given the bipartisan nature of veterans' healthcare issues and the seniority of the sponsor, it has a high probability of moving through committee. The next step is a committee vote, followed by a full Senate vote. If passed by the Senate, it would then move to the House of Representatives. The establishment and implementation of the formulary would occur after the bill becomes law, likely within 12-24 months, providing a clear timeline for increased procurement.